These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1263 related articles for article (PubMed ID: 19779718)
1. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
2. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. Shmeeda H; Tzemach D; Mak L; Gabizon A J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844 [TBL] [Abstract][Full Text] [Related]
3. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160 [TBL] [Abstract][Full Text] [Related]
4. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088 [TBL] [Abstract][Full Text] [Related]
5. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479 [TBL] [Abstract][Full Text] [Related]
7. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Shmeeda H; Mak L; Tzemach D; Astrahan P; Tarshish M; Gabizon A Mol Cancer Ther; 2006 Apr; 5(4):818-24. PubMed ID: 16648551 [TBL] [Abstract][Full Text] [Related]
8. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964 [TBL] [Abstract][Full Text] [Related]
10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468 [TBL] [Abstract][Full Text] [Related]
11. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942 [TBL] [Abstract][Full Text] [Related]
12. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Gabizon A; Shmeeda H; Horowitz AT; Zalipsky S Adv Drug Deliv Rev; 2004 Apr; 56(8):1177-92. PubMed ID: 15094214 [TBL] [Abstract][Full Text] [Related]
13. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737 [TBL] [Abstract][Full Text] [Related]
15. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275 [TBL] [Abstract][Full Text] [Related]
16. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. Chiu SJ; Marcucci G; Lee RJ Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505 [TBL] [Abstract][Full Text] [Related]
17. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105 [TBL] [Abstract][Full Text] [Related]
18. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920 [TBL] [Abstract][Full Text] [Related]
19. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697 [TBL] [Abstract][Full Text] [Related]
20. Vascular targeting of doxorubicin using cationic liposomes. Wu J; Lee A; Lu Y; Lee RJ Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]